去找了一下原文： Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
Findings
From Jan 31, to Sept 14, 2021, 1 282 928 individuals were included, of whom 687 167 (53·6%) were in the rAd26-rAd5 analysis, 358 431 (27·6%) in the ChAdOx1 nCoV-19 analysis, and 237 330 (18·5%) in the BBIBP-CorV analysis. Vaccine effectiveness after two doses was high for all three vaccines, adjusted odds ratio 0·36 (95% CI 0·35–0·37) for rAd26-rAd5, 0·32 (0·31–0·33) for ChAdOx1 nCoV-19, and 0·56 (0·55–0·58) for BBIBP-CorV. After two doses, the effect on deaths was higher than that on risk of infection: adjusted hazard ratio 0·19 (95% CI 0·18–0·21) for rAd26-rAd5, 0·20 (0·18–0·22) for ChAdOx1 nCoV-19, and 0·27 (0·25–0·29) for BBIBP-CorV. The indirectly estimated effectiveness on deaths was 93·1% (95% CI 92·6–93·5) for rAd26-rAd5, 93·7% (93·2–94·3) for ChAdOx1 nCoV-19, and 85·0% (84·0–86·0) for BBIBP-CorV following two doses. First dose effect of viral vector vaccines remained stable over time.
Until September, 2021, in Argentina, COVID-19 vaccines developed in non-replicative virus platforms were authorised and widely used in people older than 60 years: rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19 (Oxford–AstraZeneca), and the inactivated vaccine BBIBP-CorV (Sinopharm). The administration of vaccines to people older than 60 years began in January, 2021, with rAd26-rAd5 V and ChAdOx1 nCoV-19 used from February, 2021; BBIBP-CorV was used from March, 2021.
3款分别是rAd26-rAd5 (Sputnik V), ChAdOx1 nCoV-19 (Oxford–AstraZeneca), and the inactivated vaccine BBIBP-CorV (Sinopharm).
没有美国的mRNA，可能是当初产量不足，没给阿根廷？
这研究的时间段，奥密克戎变种还没出来，也不知道这数据对现在的状况有多少指导意义。